5月13日 - ** 癌症诊断公司Personalis PSNL.O 股价在盘前交易中上涨6.8%，至6.45美元
** 该公司表示，其NeXT Personal癌症检测的联邦医疗保险（Medicare）覆盖范围已扩大，用于监测接受免疫治疗的晚期实体瘤患者
** 该检测可追踪体内残留的微量癌细胞，帮助医生评估免疫疗法是否有效 - PSNL
** PSNL表示，此项决定基于一项研究，该研究显示该检测能比标准扫描更早地追踪免疫疗法反应并预测治疗结果
** 此次覆盖范围的扩大，紧随此前联邦医疗保险 (link) 将该检测纳入肺癌复发监测范围之后
** 联邦医疗保险（Medicare）是美国政府为65岁及以上人群提供的医疗保险计划
** 截至上一交易日收盘，PSNL今年以来累计下跌24.1%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.